Cancer Immunity, Vol. 5, p. 9 (7 July 2005)
نویسندگان
چکیده
Transcripts with ESTs derived exclusively or predominantly from testis, and not from other normal tissues, are likely to be products of genes with testis-restricted expression, and are thus potential cancer/ testis (CT) antigen genes. A list of 371 genes with such characteristics was compiled by analyzing publicly available EST databases. RT-PCR analysis of normal and tumor tissues was performed to validate an initial selection of 20 of these genes. Several new CT and CT-like genes were identified. One of these, CT46/HORMAD1, is expressed strongly in testis and weakly in placenta; the highest level of expression in other tissues is <1% of testicular expression. The CT46/HORMAD1 gene was expressed in 31% (34/109) of the carcinomas examined, with 11% (12/109) showing expression levels >10% of the testicular level of expression. CT46/HORMAD1 is a single-copy gene on chromosome 1q21.3, encoding a putative protein of 394 aa. Conserved protein domain analysis identified a HORMA domain involved in chromatin binding. The CT46/HORMAD1 protein was found to be homologous to the prototype HORMA domain-containing protein, Hop1, a yeast meiosis-specific protein, as well as to asy1, a meiotic synaptic mutant protein in Arabidopsis thaliana.
منابع مشابه
Cancer Immunity (28 August 2008) Vol. 8, p. 13
1First Department of Medicine, Hokkaido University School of Medicine, North 15 West 7, Kita-ku, Sapporo 060-8638, Japan 2Department of Immunology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama 700-8558, Japan 3Department of Medical Oncology, Hokkaido University Graduate School of Medicine, North 15 West 7, Kita-ku, Sapporo 06...
متن کاملCancer Immunity (5 June 2009) Vol. 9, p. 5
1Ludwig Center for Cancer Immunotherapy, Immunology Program, Sloan-Kettering Institute, New York, NY, USA 2Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA 3Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA 4Ludwig Institute for Cancer Research, New York Branch, Memorial Sloan-Kettering Cancer Center, New Yor...
متن کاملCancer Immunity (22 October 2007) Vol. 7, p. 17
1Academic Department of Clinical Oncology, Institute of Infections, Immunity and Inflammation, University of Nottingham, City Hospital, Nottingham, NG5 1PB, United Kingdom 2Dept. of Histopathology, Addenbrooke's NHS Trust, Cambridge, United Kingdom 3Dep. of Histopathology, City Hospital, Nottingham, NG5 1PB, United Kingdom 4Dep. of Pathology, Iran University of Medical Sciences, Tehran, Iran *T...
متن کاملCancer Immunity (19 February 2009) Vol. 9, p. 1
1Medical Oncology, National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany 2Department of Applied Tumor Biology, Institute of Pathology, University of Heidelberg, Heidelberg, Germany 3Hamamatsu Tissue Imaging and Analysis (TIGA) Center, BIOQUANT, University of Heidelberg, Heidelberg, Germany 4Institute of Pathology, University of Heidelberg, Heidelberg, Germany 5Depart...
متن کاملEvaluation of diffusion MR as a biomarker for nanoparticle therapy response in lymphoma
[1] Clinical Cancer Research July 1, 2009 15, 4365 [2] Seminars in Hematology Volume 44, Supplement 4, July 2007, Pages S12-S17 [3] Clinical Cancer Research March 1, 2006 12, 1606 [4] Clinical Cancer Research January 15, 2007 13, 443 [5] NMR Biomed. 2008 Nov; 21(10):1021-9. [6] PNAS July 7, 2009 vol. 106 no. 27 11394-11399 Figure 3: ADC maps for a treated animal. A steady increase in the ADC va...
متن کامل